Featured Research

from universities, journals, and other organizations

Volunteers Needed For Stanford Study Of Mysterious, Fatal Lung Disease

Date:
April 9, 2005
Source:
Stanford University School Of Medicine
Summary:
A lung disease known as idiopathic pulmonary fibrosis strikes without warning and often kills within only a few years. The Stanford University School of Medicine is one of 75 North American and European medical centers conducting a clinical trial to test if injections of a synthetic protein, which is also naturally produced by the immune system, can increase survival time for patients with this condition.

STANFORD, Calif. – A lung disease known as idiopathic pulmonary fibrosis strikes without warning and often kills within only a few years. The Stanford University School of Medicine is one of 75 North American and European medical centers conducting a clinical trial to test if injections of a synthetic protein, which is also naturally produced by the immune system, can increase survival time for patients with this condition.

"This is a very frustrating disease," said Susan Jacobs, the medical school's director of clinical research in pulmonary and critical care medicine. "People are very symptomatic with breathlessness and cough and there are currently no effective treatments."

Glenn Rosen, MD, associate professor of pulmonary and critical care medicine and director of the Interstitial Lung Disease Program at Stanford University Medical Center, is the principal investigator of the study, called the INSPIRE trial. The trial is sponsored by InterMune of Brisbane, Calif., which is providing the interferon gamma protein that is being used in the tests. Rosen is also a consultant for the company.

"The INSPIRE trial offers patients an opportunity to be part of an important study which will determine if interferon gamma improves survival," said Rosen, who runs a laboratory that examines the cellular pathways that become overactive in this disease.

"The trial also offers an opportunity to learn more about the natural history of idiopathic pulmonary fibrosis and enhance our understanding of the disease," he said.

Idiopathic pulmonary fibrosis, or IPF, develops from damage to the alveoli, the tiny air sacs in the lungs that exchange oxygen from inhaled air for carbon dioxide in the blood. Pulmonary fibrosis can develop from dozens of causes, including exposure to such environmental assaults as asbestos, metal dust or even molds.

In situations in which there is nothing in a patient's history that explains the development of fibrosis, it is known as idiopathic, medical terminology for "unknown cause."

The majority of the pulmonary fibrosis cases fall into the category of idiopathic, according to the Coalition for Pulmonary Fibrosis. The group estimates that 83,000 people in the United States have IPF, with around 31,000 new cases annually.

Whatever the cause, pulmonary fibrosis begins with an over-reactive healing response to something irritating the lungs. The alveoli become inflamed and fibrous scar tissue forms in the surrounding regions. The scarring process makes breathing difficult and reduces oxygen transfer to the blood.

No cure exists for IPF. Anti-inflammatory medications can sometimes help, but less than 10 to 15 percent of patients respond to the treatment enough to halt the scarring process, according to Jacobs and Rosen.

Despite treatment, most patients deteriorate and eventually their lungs fail. The average survival time following diagnosis is a few years; two-thirds of patients die within five years of diagnosis. The only definitive treatment for the disease is a lung transplant, but suitable donor lungs are rare and long-term survival is less than 50 percent.

In the quest for a treatment for IPF, speculation that it may be an autoimmune disease led to the idea that interferon gamma might help, as it has been used with some success in other autoimmune diseases such as multiple sclerosis. Interferon gamma is a member of naturally occurring proteins produced by the immune system to help the body launch an attack against foreign invaders. There are three classes of interferons: alpha, beta and gamma, and each of these classes has different, although sometimes overlapping, effects.

A previous clinical trial testing interferon gamma in the treatment of IPF found that while there was not an improvement in breathing ability as the disease progressed, there was a trend toward better survival in the group receiving the treatment. Jacobs said interferon gamma might offer some kind of immune protective effect.

To test the treatment in a longer-running study involving more people, a total of 600 participants will be enrolled at the centers –10 at Stanford – and the trial will run for two years following the enrollment of the last person.

Adults between the ages of 40 and 79 who have been diagnosed with IPF in the past 48 months may be eligible to participate in the INSPIRE trial. Those who meet eligibility requirements and who are enrolled will receive either interferon gamma or a placebo by subcutaneous injection three times a week for a minimum of two years. Neither the researchers nor the study participants will know who receives the active drug.

Participants will be taught to administer the injection to themselves and will need to come to Stanford five times in the first three months, then return once every three months for the duration of the study. For more information call (650) 725-8082.


Story Source:

The above story is based on materials provided by Stanford University School Of Medicine. Note: Materials may be edited for content and length.


Cite This Page:

Stanford University School Of Medicine. "Volunteers Needed For Stanford Study Of Mysterious, Fatal Lung Disease." ScienceDaily. ScienceDaily, 9 April 2005. <www.sciencedaily.com/releases/2005/03/050325224658.htm>.
Stanford University School Of Medicine. (2005, April 9). Volunteers Needed For Stanford Study Of Mysterious, Fatal Lung Disease. ScienceDaily. Retrieved September 16, 2014 from www.sciencedaily.com/releases/2005/03/050325224658.htm
Stanford University School Of Medicine. "Volunteers Needed For Stanford Study Of Mysterious, Fatal Lung Disease." ScienceDaily. www.sciencedaily.com/releases/2005/03/050325224658.htm (accessed September 16, 2014).

Share This



More Health & Medicine News

Tuesday, September 16, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

EU Ministers and Experts Meet to Discuss Ebola Reponse

EU Ministers and Experts Meet to Discuss Ebola Reponse

AFP (Sep. 15, 2014) The European Commission met on Monday to coordinate aid that the EU can offer to African countries affected by the Ebola outbreak. Duration: 00:58 Video provided by AFP
Powered by NewsLook.com
Despite The Risks, Antibiotics Still Overprescribed For Kids

Despite The Risks, Antibiotics Still Overprescribed For Kids

Newsy (Sep. 15, 2014) A new study finds children are prescribed antibiotics twice as often as is necessary. Video provided by Newsy
Powered by NewsLook.com
FDA Eyes Skin Shocks Used at Mass. School

FDA Eyes Skin Shocks Used at Mass. School

AP (Sep. 15, 2014) The FDA is considering whether to ban devices used by the Judge Rotenberg Educational Center in Canton, Massachusetts, the only place in the country known to use electrical skin shocks as aversive conditioning for aggressive patients. (Sept. 15) Video provided by AP
Powered by NewsLook.com
Respiratory Virus Spreads To Northeast, Now In 21 States

Respiratory Virus Spreads To Northeast, Now In 21 States

Newsy (Sep. 14, 2014) The respiratory virus Enterovirus D68, which targets children, has spread from the Midwest to 21 states. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins